CSL sues former exec for trade secrets theft by Eric Sagonowsky Thursday, October 17, 2019 CSL has sued a former exec who its says stole thousands of key documents as he left for competitor Pharming.
Want to thrive, pharma? Forget 'me-too' drugs, CSL chief says by Eric Sagonowsky Monday, January 14, 2019 Pharma is too preoccupied with short-term growth, so it's going the easier me-too route rather than focusing on "transformative" therapies, the CEO said.
Shire eyes blockbuster sales with new HAE drug Takhzyro by Carly Helfand Friday, August 24, 2018 Shire got a brand-new approval that could help it dominate the hereditary angioedema market for years—and rack up blockbuster sales in the process.
Shire scores new FDA thumbs-up for HAE drug Cinryze by Arlene Weintraub Thursday, June 21, 2018 Shire's ability to market Cinryze for children as young as 6 with HAE. That could help Shire fend off an all-out attack from CSL.
Haegarda launch timing, pricing were on target, CSL CEO says by Eric Sagonowsky Friday, January 19, 2018 CSL may have faced resistance from Shire when it launched Haegarda last year, but CEO Paul Perreault says the decision to go ahead was worth it.
CSL launches Cinryze rival despite Shire's best efforts by Carly Helfand Thursday, July 20, 2017 Shire fought hard to stop it, but no dice: CSL has now launched its hereditary angioedema med Haegarda—and at a big discount, too.
